Immunovant IMVT 深 滬
等待開盤 08-01 09:30:00 美东时间
38.62
-0.860
-2.18%
華盛通- 最 高39.32
- 今 開39.31
- 成交量 66.96万股
- 最 低 38.00
- 昨 收 39.48
- 總市值 79.71亿
- 52周最高 41.23
- 市盈率 靜 --
- 換手率 0.32%
- 52周最低 14.32
- 委 比 -96.57%
- 總股本 2.06亿
- 歷史最高 53.75
- 量 比 0.69
- 振 幅 3.34%
- 歷史最低 3.145
- 每 手 1
- 風險率 6.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Insiders Cash Out at Immunovant, Helmerich & Payne, SharkNinja, PBF Energy, Venture Global
Insiders have been trading these 5 stocks: (($IMVT)), (($HP)), (($SN)), (($PBF)...
07-25 21:01
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Immunovant, Inc. announced it will report its Q1 2026 financial results on August 6, 2026 before the market opens. Roivant Sciences Ltd., Immunovant's majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that day, including a business update for Immunovant. Registration links and details are available on the Immunovant website.
07-23 20:05
Larimar, Cytokinetics, Itau, Global-e, Immunovant Shake-Up
Insiders have been trading these 5 stocks: (($LRMR)), (($CYTK)), (($ITUB)), (($...
07-11 21:01
美股大行评级 | Bernstein上调闪迪目标价从1700美元升至3000美元；大摩上调谷歌-A目标价从375美元升至415美元
今日重点评级关注：Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元；康托·菲茨杰拉德：维持BioCryst制药"超配"评级，目标价从27美元升至29美元
07-01 10:40
Citigroup Maintains Buy on Immunovant, Raises Price Target to $61
Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $57 to $61.
07-01 02:49
美股大行评级 | 市值直指1.8万亿美元？瑞银给出美光1600美元天价目标！华尔街绩前集体上调迈威尔科技目标价
今日重点评级关注：Canaccord Genuity：维持Dakota Gold"投机性买入"评级，目标价从16美元升至18美元；瑞杰金融：上调Tectonic Therapeutic评级至"强烈买入"，目标价从76美元升至81美元
05-27 17:33
美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元
05-22 10:18
HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $40
HC Wainwright & Co. analyst Douglas Tsao maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $35 to $40.
05-21 19:12
美股牛股 | TE飙升26%，获罗斯资本反驳做空机构对其质疑；TAT科技大涨21%
TE飙升26%，获罗斯资本反驳做空机构对其质疑；TAT科技大涨21%，Q1每股盈利、销售额均超预期；SLS大涨18%，关键期试验临床数据即将公布>>
05-21 19:32
